Fusion Pharmaceuticals Inc.
Fusion Pharmaceuticals Inc. (FUSN) Revenue
Annual & quarterly revenue history · segment & region breakdown
FUSN · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsFusion Pharmaceuticals Inc. trailing twelve-month (TTM) revenue is $0.04B, an increase of 41.55% year-over-year from $0.00B in FY2023.
Revenue trend
2023 – 2017 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-12-31 | $0.00B | +$0.00B | +41.55% |
| 2022-12-31 | $0.00B | +$0.00B | +1.46% |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare FUSN revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Fusion Pharmaceuticals Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Fusion Pharmaceuticals Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Fusion Pharmaceuticals Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
FUSN revenue · 4 questionsFUSN's trailing twelve-month (TTM) revenue is $0.04B. That is an increase of 41.55% year-over-year from $0.00B in FY2023.
▸ Source: FMP · Fusion Pharmaceuticals Inc. SEC filings · GAAP · Fusion Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026